Interferon Therapy for Kaposi Sarcoma Associated with the Acquired Immunodeficiency Syndrome (AIDS) (1989)

Editorials1 March 1989Interferon Therapy for Kaposi Sarcoma Associated with the Acquired Immunodeficiency Syndrome (AIDS)Jerome E. Groopman, MD, David T. Scadden, MDJerome E. Groopman, MDSearch for more papers by this author, David T. Scadden, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-110-5-335 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe observation that recombinant interferon-alpha is an active antineoplastic agent in Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS) grew out of the initial studies of this agent by Krown and colleagues nearly 5 years ago ( 1 ). A clear role for interferon-alpha in therapy for this neoplasm is now emerging.Kaposi sarcoma is the commonest neoplastic complication of AIDS, occurring in approximately 40% of patients. The marked disparity in the incidence of Kaposi sarcoma in homosexual (approximately 40%) when compared with the incidence in heterosexual (approximately 10%) patients suggests a cause of the sarcoma that is more...References1. KrownRealCunningham-Rundles SFS. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med. 1983;308:1071-6. CrossrefMedlineGoogle Scholar2. Groopman J. AIDS-related Kaposi's sarcoma: therapeutic modalities. Semin Hematol. 1987;24(3 Suppl 2):5-8. MedlineGoogle Scholar3. NakamuraSalahuddinBiberfeld SSP. Kaposi's sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4+ T cells. Science. 1988;242:426-30. CrossrefMedlineGoogle Scholar4. MitsuyasuTaylorGlaspyFahey RJJJ. Heterogeneity of epidemic Kaposi's sarcoma: implications for therapy. Cancer. 1986;57(8 Suppl): 1657-61. CrossrefMedlineGoogle Scholar5. Vadhan-RajWongGnecco SGC. Immunological variables as predictors of prognosis in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome. Cancer Res. 1986;46:417-25. MedlineGoogle Scholar6. BordenBall EL. Interferons: biochemical, cell growth inhibitory, and immunological effects. Prog Hematol. 1981;12:299-339. MedlineGoogle Scholar7. BordenHoganVoelkel ETJ. Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells. Cancer Res. 1982;42:4948-53. MedlineGoogle Scholar8. CheesmanRubinStewart SRJ. Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects of cytomegalovirus and herpes simplex viral infections. N Engl J Med. 1979;300:1345-9. CrossrefMedlineGoogle Scholar9. GroopmanGottliebGoodman JMJ. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with acquired immunodeficiency syndrome. Ann Intern Med. 1984;100:671-6. LinkGoogle Scholar10. VolberdingValeraRothmanGee PRJG. Alpha interferon therapy of Kaposi's sarcoma in AIDS. Ann NY Acad Sci. 1984;437:439-46. CrossrefMedlineGoogle Scholar11. RiosMansellNewellReubenHershGutterman APGJEJ. Treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma with lymphoblastoid interferon. J Clin Oncol. 1985;3:506-12. CrossrefMedlineGoogle Scholar12. GelmannPrebleSteis EOR. Human lymphoblastoid interferon treatment of Kaposi's sarcoma in the acquired immune deficiency syndrome. Clinical response and prognostic parameters. Am J Med. 1985;78:737-41. CrossrefMedlineGoogle Scholar13. RealOettgenKrown FHS. Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol. 1986;4:544-51. CrossrefMedlineGoogle Scholar14. KrownRealVadhan-Raj SFS. Kaposi's sarcoma and the acquired immune deficiency syndrome. Treatment with recombinant interferon alpha and analysis of prognostic factors. Cancer. 1986;57 (8 Suppl):1662-5. CrossrefMedlineGoogle Scholar15. AbramsVolberding DP. Alpha interferon therapy of AIDS-associated Kaposi's sarcoma. Semin Oncol. 1987;14(2 Suppl 2):43-7. MedlineGoogle Scholar16. de WitSchattenkerkBoucherBakkerVeenhofDanner RJCPKS. Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma. Lancet. 1988;2:1214-7. CrossrefMedlineGoogle Scholar17. Krown S. The role of interferon in the therapy of epidemic Kaposi's sarcoma. Semin Oncol. 1987;14(2 Suppl 3):27-33. MedlineGoogle Scholar18. KrownGoldReal SJF. Interferon alfa-2a ± vinblastine (VLB) in AIDS-associated Kaposi's sarcoma (KS/AIDS): therapeutic activity, toxicity and effects on HTLV-II I/LAV viremia [Abstract]. J Interferon Res. 1986;6:3. Google Scholar19. RiosMansellNewel APG. The use of lymphoblastoid interferon Hu IFN alpha (LY) and vinblastine in the treatment of acquired immunodeficiency syndrome (AIDS) related Kaposi's sarcoma (KS) [Abstract]. Proc Am Soc Clin Oncol. 1985;4:6. Google Scholar20. LonbergOdajnykKrigel MCR. Sequential and simultaneous alpha 2 interferon (IFN) and VP16 in epidemic Kaposi's sarcoma [Abstract]. Proc Am Soc Clin Oncol. 1985;4:2. Google Scholar21. HoHartshornRota DKT. Recombinant human interferon alfa-Á suppresses HTLV-III replication in vitro. Lancet. 1985;1:602-4. CrossrefMedlineGoogle Scholar22. LaneKovacsFeinberg HJJ. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet. 1988;2:1218-22. CrossrefMedlineGoogle Scholar23. HartshornVogtChou KMT. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrobial Agents Chemother. 1987;31:168-72. CrossrefMedlineGoogle Scholar24. KrownBundowGansbacher SDB. Interferon-alpha plus zidovudine: a phase I trial in AIDS-associated Kaposi's sarcoma (KS). Proceedings, IV International Conference on AIDS, Stockholm, Sweden, June 13-16, 1988. Abstract 3627. Google Scholar25. FischlReeseDearmas MJL. Phase I study of interferonalpha and AZT in patients with AIDS-related Kaposi's sarcoma. Proceedings, IV International Conference on AIDS, Stockholm, Sweden, June 13-16, 1988. Abstract 3133. Google Scholar26. DeytonKovacsMasur LJH. Combination trial (Phase I-II) of zidovudine with lymphoblastoid interferon alpha in patients with AIDS and Kaposi's sarcoma. Proceedings, IV International Conference on AIDS, Stockholm, Sweden, June 13-16, 1988. Abstract 3628. Google Scholar27. GroopmanMitsuyasuDeLeoOetteGolde JRMDD. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med. 1987;317:593-8. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New England Deaconess Hospital Harvard Medical School Boston, Massachusetts PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByLarge Intestine (Colon)Combination of Antiangiogenic Therapy with Other Anticancer TherapiesInterferons Alpha, Beta, and OmegaInterleukin-4 in the treatment of AIDS-related Kaposi’s sarcomaOverview of the Management of AIDS-Related Kaposi's SarcomaA systems approach to cancer therapyAngiogenesis and cancer metastases: therapeutic approachesLower extremity lymphedema caused by acquired immune deficiency syndrome – related Kaposi's sarcoma: Case report and review of the literaturePro‐inflammatory cytokines in a ruminant model: Pathophysiological, pharmacological, and therapeutic aspectsMajor Therapeutic Uses of InterferonsTreatment of poor prognosis epidemic Kaposi's sarcoma with doxorubicin, bleomycin, vindesine and recombinant human granulocyte-monocyte colony stimulating factor (rh GM-CSF)Treatment of Kaposi’s Sarcoma with Interferon-α and Other Biological Response ModifiersKaposi’s Sarcoma Presenting as Generalized LymphedemaInterferon—A Major Regulator of Natural Killer Cell-Mediated CytotoxicityKaposi's sarcoma?-Cyclodextrin tetradecasulfate/tetrahydrocortisol�minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic lewis lung carcinomaMinocycline in combination with chemotherapy or radiation therapy in vitro and in vivoConsiderations in the Treatment of Patients With Acquired Immunodeficiency Syndrome at HomeAIDS-associated Kaposi'i sarcoma and the mechanisms of interferon alpha'a activity; a riddle within a puzzleAre There Still Indications for Single Agent High-Dose Interferon-Alpha against AIDS-Associated Kaposi's Sarcoma?Recent Advances in DermatologyBiologic Response Modifiers in Primary Immunodeficiency DisordersAvi Hassner, MD, Daniel C. Adelman, MDAntiretroviral therapy in combination with interferon for AIDS-related Kaposi's sarcomaKaposi's Sarcoma and AIDSManagement of AIDS and its neoplastic complicationsCombined zidovudine and interferon-alpha treatment in patients with AIDS-associated Kaposi's sarcomaDevelopment of angiogenesis inhibitors for clinical applicationsAnti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant friend erythroleukemia cells. VIII. Role of the immune system in the inhibition of visceral metastasesClinical Use of Biologic Response Modifiers in Cancer Treatment: An Overview Part I. The InterferonsConsiderations in the Treatment of Acquired Immunodeficiency Syndrome Patients at HomeKaposi Sarcoma and Alpha-Interferon TherapyRobert L. Krigel, MD 1 March 1989Volume 110, Issue 5Page: 335-337KeywordsAIDSHeterosexualsHomosexualsInterferonsKaposi sarcomaSarcoma Issue Published: 1 March 1989 PDF DownloadLoading ...